High-flow nasal oxygen: a safe, efficient treatment for COVID-19 patients not in an ICU

Guy, T.; Créac'hcadec, Audrey; Ricordel, Charles; Salé, A.; Arnouat, Baptiste; Bizec, Jean-Louis; Langelot, Marie; Lineau, C.; Marquette, David; Martín, F. de Juan; Léderlin, Mathieu; Jouneau, S.

doi:10.1183/13993003.01154-2020

Cited by 69 publications

(71 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Its importance once grew more during the COVID-19 pandemic because of its close association with the respiratory system [4] . High-flow nasal oxygen is found to be a safe and efficient treatment for COVID-19 patients who are not in an ICU [5] . The WHO says that 15 percent of COVID-19 patients require medical oxygen because of breathing difficulties [6] .…”

Section: Introductionmentioning

confidence: 98%

WITHDRAWN: Medical oxygen supply during COVID-19: A study with specific reference to State of Andhra Pradesh, India

Bikkina

Manda

Rao

2021

Materials Today: Proceedings

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 98%

WITHDRAWN: Medical oxygen supply during COVID-19: A study with specific reference to State of Andhra Pradesh, India

Bikkina

Manda

Rao

2021

Materials Today: Proceedings

View full text Add to dashboard Cite

“…Compared to standard oxygen therapy, HFNC therapy reduced 90-day mortality and increased the number of ventilator free days, in hARF due to non-COVID-19 causes [ 112 ]. Small case series suggest HFNC may decrease the need for intubation in COVID-19 patients more effectively than standard oxygen therapy, and large uncontrolled case series of application outside the ICU suggests HFNC and CPAP have similar efficacy, but these results are unconfirmed and patient groups may not be comparable [ 108 , 109 , 113 , 114 ].…”

Section: Summary Of Recommendationsmentioning

confidence: 99%

“…The application of CPAP and HFNC should not delay intubation and mechanical ventilation in patients who fail to respond to a non-invasive approach. CPAP and HFNC therapy are classified as aerosol generating procedures and should be used with healthcare professionals in full personal protective equipment (PPE) [ 113 , 139 ]. The nature of aerosol generation or dispersion when using CPAP and HFNC has been explored using a range of imaging, particle sizing and virus sampling studies producing mixed results [ 110 , 140 – 142 ].…”

Section: Summary Of Recommendationsmentioning

confidence: 99%

Management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline

et al. 2021

View full text Add to dashboard Cite

IntroductionHospitalised patients with coronavirus disease 19 (COVID-19) as a result of SARS-CoV-2 infection have a high mortality rate and frequently require non-invasive respiratory support or invasive ventilation. Optimising and standardising management through evidence-based guidelines may improve quality of care and therefore patient outcomes.MethodsA task force from the European Respiratory Society and endorsed by the Chinese Thoracic Society identified priority interventions (pharmacological and non-pharmacological) for the initial version of this “living guideline” using the PICO (population, intervention, comparator, outcome) format. The GRADE approach was used for assessing the quality of evidence and strength of recommendations. Systematic literature reviews were performed, and data pooled by meta-analysis where possible. Evidence tables were presented and evidence to decision frameworks were used to formulate recommendations.ResultsBased on the available evidence at the time of guideline development (February 20th, 2021) the panel makes a strong recommendation in favour of the use of systemic corticosteroids in patients requiring supplementary oxygen or ventilatory support, and for the use of anticoagulation in hospitalised patients. The panel makes a conditional recommendation for IL-6 receptor antagonist monoclonal antibody treatment and high flow nasal oxygen or continuous positive airway pressure in patients with hypoxaemic respiratory failure. The panel make strong recommendations against the use of hydroxychloroquine and lopinavir-ritonavir. Conditional recommendations are made against the use of azithromycin, hydroxychloroquine and azithromycin, colchicine, and remdesivir, in the latter case specifically in patients requiring invasive mechanical ventilation. No recommendation was made for remdesivir in patients requiring supplemental oxygen. Further recommendations for research are made.ConclusionThe evidence base for management of COVID-19 now supports strong recommendations in favour and against specific interventions. These guidelines will be regularly updated as further evidence becomes available.

show abstract

“…Recent experience in COVID-19 related Acute respiratory failure (21 publications including 1553 patients) 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 with HFNC, CPAP and Bi-Level Ventilation (using negative pressure rooms in only one series 15 ) shows average success of 60%, 55% and 59%, respectively, and an average infection rate in health professionals of 5.2%, less than the 12% reported in New York City among the staff not necessarily working with NIRT. 28 …”

mentioning

confidence: 99%

Non-invasive respiratory support paths in hospitalized patients with COVID-19: proposal of an algorithm

Scala

2021

Pulmonology

View full text Add to dashboard Cite

High-flow nasal oxygen: a safe, efficient treatment for COVID-19 patients not in an ICU

Cited by 69 publications

References 9 publications

WITHDRAWN: Medical oxygen supply during COVID-19: A study with specific reference to State of Andhra Pradesh, India

WITHDRAWN: Medical oxygen supply during COVID-19: A study with specific reference to State of Andhra Pradesh, India

Management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline

Non-invasive respiratory support paths in hospitalized patients with COVID-19: proposal of an algorithm

Contact Info

Product

Resources

About